These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7879813)

  • 1. Re-examination of clinical aspects of pharmacoeconomic analysis.
    Rubenstein EB; Elting LS
    Am J Hosp Pharm; 1994 Dec; 51(23):2970-3. PubMed ID: 7879813
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
    Zbrozek AS; Cantor SB; Cardenas MP; Hill DP
    Am J Hosp Pharm; 1994 Jun; 51(12):1555-63. PubMed ID: 8092156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ondansetron and granisetron on chemotherapy-induced emesis in adults: the need for comparative pharmacoeconomic data.
    Hedayati S; Moatti JP; Seitz JF
    Clin Ther; 1994; 16(3):569-80. PubMed ID: 7923321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
    Lachaine J; Laurier C; Langleben A; Vaillant L
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):105-12. PubMed ID: 10612010
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacoeconomic analyses: whose perspective counts and costs the most?
    Rubenstein EB; Elting LS
    Am J Hosp Pharm; 1994 Jun; 51(12):1564-9. PubMed ID: 8092157
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness, not cost containment.
    Zbrozek AS
    Am J Hosp Pharm; 1994 Jun; 51(12):1569-71. PubMed ID: 8092158
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for vomiting caused by cancer chemotherapy.
    Med Lett Drugs Ther; 1993 Dec; 35(912):124-6. PubMed ID: 8264505
    [No Abstract]   [Full Text] [Related]  

  • 8. Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
    Kris MG
    Important Adv Oncol; 1994; ():165-77. PubMed ID: 8206488
    [No Abstract]   [Full Text] [Related]  

  • 9. [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
    Czeglédi F; Baki M
    Orv Hetil; 1994 Oct; 135(44):2415-9. PubMed ID: 7970661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ondansetron for preventing nausea and vomiting.
    Cooke CE; Mehra IV
    Am J Hosp Pharm; 1994 Mar; 51(6):762-71. PubMed ID: 8010314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
    Goldspiel BR; Kohler DR
    Obstet Gynecol; 1994 Sep; 84(3):483-4. PubMed ID: 8058256
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of cytostatic-induced vomiting with high-dose metoclopramide].
    Ell C; König HJ
    Dtsch Med Wochenschr; 1983 Jun; 108(24):962. PubMed ID: 6851896
    [No Abstract]   [Full Text] [Related]  

  • 16. Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
    Krobbuaban B; Pitakpol S; Diregpoke S
    J Med Assoc Thai; 2008 May; 91(5):669-74. PubMed ID: 18672630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children].
    Calamandrei M; Andreuccetti T; Crescioli M; Messeri A; Sarti A; Sestini G; Busoni P
    Cah Anesthesiol; 1994; 42(1):19-23. PubMed ID: 8076228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difficulties in assessing appropriate ondansetron use.
    Schwarz LR
    Am J Hosp Pharm; 1993 Dec; 50(12):2523-4; author reply 2525-6. PubMed ID: 8122685
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventing emesis in lung cancer patients.
    J Support Oncol; 2007 Feb; 5(2):79-80. PubMed ID: 17348365
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
    Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
    Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.